3,5-Dimethyl-1,2-dithiolan-4-one, trans- | 72770-97-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二硫杂环戊烷
• 英文名称: 3,5-Dimethyl-1,2-dithiolan-4-one, trans-
• 英文别名: (3S,5S)-3,5-dimethyldithiolan-4-one
• CAS: 72770-97-9
• 化学式: C₅H₈OS₂
• 分子量: 148.25
• InChiKey: DYTKSLFUSUKZJN-IMJSIDKUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  67.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-Dimethyl-1,2-dithiolan-4-one, trans- 在 sodium tetrahydroborate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 7.0h， 以42%的产率得到
  参考文献：
  名称：

  [EN] CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS
  [FR] PROMÉDICAMENTS OLIGONUCLÉOTIDIQUES À BASE DE PHOSPHATE MODIFIÉS PAR UN DISULFURE CYCLIQUE

  摘要：

  This invention relates to a compound comprising a structure of formula (I): cyclic disulfide moiety — phosphorus coupling group (I). The cyclic disulfide moiety has the structure of (C-I), (C-II), or (C-III). This invention also relates to an oligonucleotide comprising one or more compounds that comprise the structure of formula (I), wherein at least one phosphorus coupling group contains a nucleoside or oligonucleotide. The invention also relates to a pharmaceutical composition comprising the oligonucleotide described herein and a method of reducing or inhibiting the expression of a target gene by administering to the subject a therapeutically effective amount of the oligonucleotide described herein.

  公开号：

  WO2022147214A2
• 作为产物：
  描述：

  2,4-二溴-3-戊酮 在 1,2,3,4,5,6,7,8-八硫杂环辛烷 、 sodiumsulfide nonahydrate 作用下， 反应 20.33h， 以31%的产率得到3,5-Dimethyl-1,2-dithiolan-4-one, trans-
  参考文献：
  名称：

  [EN] CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS
  [FR] PROMÉDICAMENTS OLIGONUCLÉOTIDIQUES À BASE DE PHOSPHATE MODIFIÉS PAR UN DISULFURE CYCLIQUE

  摘要：

  This invention relates to a compound comprising a structure of formula (I): cyclic disulfide moiety — phosphorus coupling group (I). The cyclic disulfide moiety has the structure of (C-I), (C-II), or (C-III). This invention also relates to an oligonucleotide comprising one or more compounds that comprise the structure of formula (I), wherein at least one phosphorus coupling group contains a nucleoside or oligonucleotide. The invention also relates to a pharmaceutical composition comprising the oligonucleotide described herein and a method of reducing or inhibiting the expression of a target gene by administering to the subject a therapeutically effective amount of the oligonucleotide described herein.

  公开号：

  WO2022147214A2

文献信息

• [EN] CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS<br/>[FR] PROMÉDICAMENTS OLIGONUCLÉOTIDIQUES À BASE DE PHOSPHATE MODIFIÉS PAR UN DISULFURE CYCLIQUE
  申请人：[en]ALNYLAM PHARMACEUTICALS, INC.

  公开号：WO2022147214A2

  公开（公告）日：2022-07-07

  This invention relates to a compound comprising a structure of formula (I): cyclic disulfide moiety — phosphorus coupling group (I). The cyclic disulfide moiety has the structure of (C-I), (C-II), or (C-III). This invention also relates to an oligonucleotide comprising one or more compounds that comprise the structure of formula (I), wherein at least one phosphorus coupling group contains a nucleoside or oligonucleotide. The invention also relates to a pharmaceutical composition comprising the oligonucleotide described herein and a method of reducing or inhibiting the expression of a target gene by administering to the subject a therapeutically effective amount of the oligonucleotide described herein.
• WO2024006999A2
  申请人：——

  公开号：——

  公开（公告）日：——